Moderna Stock Today
| MRNA Stock | USD 54.35 5.81 11.97% |
Performance 0High 6 · Contained | Odds Of Distress HighLow 9 · Low |
Moderna currently maintains a market price of $54.35, with performance measured at a 11.97% increase on the day with an intraday range between $48.98 and $57.78. Moderna currently reflects 9% projected probability of financial distress, aligning with a relatively small probability. Moderna has produced modest risk-adjusted performance over the past 90 trading days. The performance scores are based on the time frame from February 7, 2026 to May 8, 2026. Learn more.
IPO Date 7th of December 2018 | Asset Type Stock | Category Healthcare | Classification Health Care |
Moderna (MRNA) is listed on NASDAQ Exchange in USA. Moderna operates within the Biotechnology segment. For market cap analysis, Moderna is currently valued at $19.26 billion and falls into the large-cap segment of biotechnology companies. Supporting market cap data includes about 396.79 million shares outstanding, enterprise value near $14.86 billion, and a workforce of about 4,700 people. Moderna has 59.44 million shares sold short (9.78 days to cover). The gap between operating margin (-131.1%) and net margin (-143.55%) suggests significant non-operating costs such as interest or taxes. Moderna is a research-driven pharmaceutical developer where revenue is driven by pipeline advancement, approvals, and patent-protected revenue. MRNA has return on total asset (ROA) of -13.09% consistent with unprofitable capital deployment. Negative, with expenses exceeding revenue at this margin level. Moderna also reports a return on stockholder's equity (ROE) of -36.56%, suggesting that it is not yet earning a positive return on equity. Moderna financial risk analysis Ownership Allocation The majority of Moderna's outstanding shares are owned by institutions. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors.
Check Moderna Ownership Details
Average Analyst RecommendationFinancial Strength
Debt LevelsModerna posted a Net Debt To EBITDA of 0.25x, a Debt To Equity of 0.23x, and $712.4 million in Long Term Debt for the reported period. Supporting metrics include a Long Term Debt To Capitalization of 10.0% and $27.6 million in Long Term Debt Total, which analysts use to evaluate Moderna's operational efficiency.
View Moderna Diagnostics
Sentiment-to-Price Context for Moderna
As of 2026-05-08, prevailing market sentiment toward Moderna appears moderately positive, based on limited recent coverage and sentiment signals. Tracking the average sentiment trend over time adds useful analytical context for the company.
Open Interest Against 2026-07-17 Moderna Option Contracts
For July 17, 2026, Moderna options show the following chain structure. Contract count currently stands at 80, split across 37 calls and 43 puts. Primary chain signals include implied volatility near 0.83, put/call open-interest ratio around 0.81, and max pain near strike 41.0. View the full chain for strike-level positioning. View Options.Open interest data for Moderna summarizes outstanding contracts across maturities. The relationship between open interest and Moderna price helps frame market activity.
ESG SustainabilityModerna posted an ESG Environmental Score of 60.87, an ESG Governance Score of 52.40, and an ESG Social Score of 63.52 for the reported period. ESG positioning for Moderna is consistent with the broader Biotechnology average. ESG reporting provides a structured lens on operational sustainability and oversight consistency. The data reflects observed ESG disclosures.
Environmental | Governance | Social |
Stock Notable Updates
| Legal Name | Moderna Inc |
| CEO & Director | Stphane Bancel |
| President | Stephen MD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare, (View all Sectors) |
Moderna posted a Gross Profit Margin of 77.0%, an Operating Margin of -131.1%, and a Return On Equity of -31.0% for the reported period. Capital allocation and earnings structure point to Moderna having pressured financial positioning. The earnings picture reflects near-term margin compression relative to deployed assets.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.22 | 0.16 |
|
| |||||
| Gross Profit Margin | 77.00% | 55.35% |
|
| |||||
| Total Current Liabilities | $2.42 billion | $1.99 billion |
|
| |||||
| Non Current Liabilities Total | $995.37 million | $1.7 billion |
|
| |||||
| Total Assets | $9.98 billion | $12.34 billion |
|
| |||||
| Total Current Assets | $5.99 billion | $6.54 billion |
|
|
Current Assets
Moderna posted $10.0 billion in Total Assets, a Return On Tangible Assets of -22.0%, and a Debt To Assets of 16.0% for the reported period. Supporting metrics include $25.8 million in Intangible Assets, which analysts use to evaluate Moderna's operational efficiency.
Earnings per Share Projection vs Actual
Analyst consensus on Moderna's EPS captures the range of professional forecasts and their trajectory over time. An operating margin of -166.0% frames the cost structure behind Moderna's reported EPS. Comparing Moderna's EPS against revenue growth and cash conversion clarifies earnings quality.
For Moderna, estimated EPS values represent current analyst expectations and remain subject to revision. EPS TTM is backward-looking and may diverge from future outcomes.
Top Institutional Holders
Institutional Holdings refers to the ownership stake in Moderna held by large financial organizations. These institutions can acquire significant blocks of Moderna's shares and often influence management decisions. Rising institutional interest in Moderna may signal improving fundamentals or growing market confidence.| Instituion | Recorded On | Shares | |
| Amvescap Plc. | 2025-12-31 | 7 M | |
| D. E. Shaw & Co Lp | 2025-12-31 | 5.2 M | |
| Flagship Ventures Management, Inc. | 2025-12-31 | 4.6 M | |
| Charles Schwab Investment Management Inc | 2025-12-31 | 4.6 M | |
| Bnp Paribas Arbitrage, Sa | 2025-12-31 | 4.2 M | |
| The Goldman Sachs Group Inc | 2025-12-31 | 4 M |
Moderna Historical Income Statement
Interest Expense stood at $10 million as of December 31, 2025. Meanwhile, Selling General Administrative remains stable near $1.02 billion, although Total Revenue is broadly unchanged around $1.94 billion. View More FundamentalsModerna Against Markets
| MRNA | 11.97 | ||||
| NYA | 0.30 |
| Competition | Compare Correlations |
Stock Overview, Methodology & Data Sources
The stock is in a buyout trend. Moderna was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Moderna employs 4,700 people. Headquarters are in 325 Binney Street, Cambridge, MA, United States, 02142. Recent market snapshot indicates market cap 19.26 billion, P/E 6.37. Moderna operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Operating metrics are tied to how the market is pricing risk. Relatively high trading activity may support tighter spreads and execution efficiency.
Methodology
Unless otherwise specified, financial data for Moderna is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Moderna (USA Stocks:MRNA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Moderna may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Moderna Corporate Management
| Patrick Bergstedt | Senior Vice President of Commercial Vaccines | Profile | |
| Charbel MPH | Senior VP & Head of Global Regulatory Science | Profile | |
| John Lepore | Senior Vice President of Government Engagement | Profile | |
| Jerh Collins | Chief Technical Operations & Quality Officer | Profile | |
| Juan Andres | Pres Expansion | Profile | |
| Jos MD | Chief Safety Officer | Profile |